BL - 1020 + BL - 1020 + Placebo + Risperidone
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jul 1, 2008 → Sep 1, 2009
NCT ID
NCT00567710About BL - 1020 + BL - 1020 + Placebo + Risperidone
BL - 1020 + BL - 1020 + Placebo + Risperidone is a phase 2 stage product being developed by BioLineRx for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00567710. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00567710 | Phase 2 | Completed |
Competing Products
20 competing products in Schizophrenia